ZTSZoetis Inc.

$54B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$2.2B+1.4% YoY

Gross Profit

$1.6B70.5% margin

Operating Income

$846M38.1% margin

Net Income

$631M28.4% margin

EPS (Diluted)

$1.41

QoQ Revenue Growth

-4.2%

Cash Flow

Operating Cash Flow

$587M

Free Cash Flow

$438M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$14.1B

Total Liabilities

$9.4B

Stockholders' Equity

$4.7B

Cash & Equivalents

$1.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.2B	$2.2B	+1.4%
Gross Profit	$1.6B	$1.5B	+3.7%
Operating Income	$846M	$801M	+5.6%
Net Income	$631M	$599M	+5.3%

Revenue Segments

Dogs and Cats

$1.5B68%

Cattle

$358M16%

Swine

$111M5%

Poultry

$106M5%

Horses

$65M3%

Fish

$53M2%

Geographic Segments

United States Segment

$1.2B54%

International Segment

$1.0B46%

ZTS Q1 2025 Earnings — Zoetis Inc. Revenue & Financial Results | Market Cap Arena